Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial

[1]  R. Hills,et al.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  H. Uno,et al.  Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. , 2010, Blood.

[3]  C. Bloomfield,et al.  P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. , 2010, Blood.

[4]  H. Gundacker,et al.  Sequential phase II Southwest Oncology Group studies (S0112 and S0301) of daunorubicin and cytarabine by continuous infusion, without and with ciclosporin, in older patients with previously untreated acute myeloid leukaemia , 2010, British journal of haematology.

[5]  U. Mony,et al.  Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia , 2010, Leukemia.

[6]  K. Ardeshna,et al.  Donor Lymphocyte Infusions Induce High Response Rates and Durable Salvage in Relapsed Hodgkin Lymphoma Post T Cell Depleted Allogeneic Transplantation. , 2009 .

[7]  R. Hills,et al.  Attempts to Optimise Induction and Consolidation Chemotherapy in Patients with Acute Myeloid Leukaemia: Results of the MRC AML15 Trial. , 2009 .

[8]  R. Hills,et al.  The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial , 2009, British journal of haematology.

[9]  N. Russell,et al.  Sequential Influences of Leukemia-Specific and Genetic Factors on P-Glycoprotein Expression in Blasts from 817 Patients Entered into the National Cancer Research Network Acute Myeloid Leukemia 14 and 15 Trials , 2007, Clinical Cancer Research.

[10]  R. Fanin,et al.  The role of MDR‐related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype , 2007, Hematological oncology.

[11]  M. Gobbi,et al.  Case–control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients , 2007, British journal of haematology.

[12]  N. Casadevall,et al.  Flt3 Internal Tandem Duplication and P-Glycoprotein Functionality in 171 Patients with Acute Myeloid Leukemia , 2006, Clinical Cancer Research.

[13]  P. Sonneveld,et al.  The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. , 2005, Blood.

[14]  G. Ehninger,et al.  MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia , 2005, British journal of haematology.

[15]  N. Russell,et al.  Reproducible measurements of AML blast p-glycoprotein function in 2 center analyses. , 2005, Blood.

[16]  M. Pallis,et al.  Flow cytometric measurement of functional and phenotypic P-glycoprotein. , 2005, Methods in molecular medicine.

[17]  D. Mahadevan,et al.  Targeting the multidrug resistance-1 transporter in AML: molecular regulation and therapeutic strategies. , 2004, Blood.

[18]  R. Advani,et al.  Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. Solary,et al.  Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. , 2003, Blood.

[21]  D. Steinbach,et al.  Contrary to adult patients, expression of the multidrug resistance gene (MDR1) fails to define a poor prognostic group in childhood AML , 2003, Leukemia.

[22]  G. Schuurhuis,et al.  Function of the ABC transporters, P-glycoprotein, multidrug resistance protein and breast cancer resistance protein, in minimal residual disease in acute myeloid leukemia. , 2003, Haematologica.

[23]  M. Gobbi,et al.  Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients. , 2002, Journal of experimental & clinical cancer research : CR.

[24]  M. Caligiuri,et al.  Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. , 2002, Blood.

[25]  N. Russell,et al.  P-glycoprotein in Acute Myeloid Leukaemia: Therapeutic Implications of its Association With Both a Multidrug-resistant and an Apoptosis-resistant Phenotype , 2002, Leukemia & lymphoma.

[26]  J. Doroshow,et al.  Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. , 2001, Blood.

[27]  P. Sonneveld,et al.  MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. , 2001, Blood.

[28]  N. Russell,et al.  Contrasting in vitro effects for the combination of fludarabine, cytosine arabinoside (Ara-C) and granulocyte colony-stimulating factor (FLAG) compared with daunorubicin and Ara-C in P-glycoprotein-positive and P-glycoprotein-negative acute myeloblastic leukaemia. , 2000 .

[29]  P. Sonneveld,et al.  P-glycoprotein in primary acute myeloid leukemia and treatment outcome of idarubicin/cytosine arabinoside-based induction therapy , 2000, Leukemia.

[30]  M. Grever,et al.  Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study. , 1999, Blood.

[31]  G. Papa,et al.  P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. , 1999, Leukemia research.

[32]  N. Russell,et al.  Early allogeneic transplantation for refractory or relapsed acute leukaemia following remission induction with FLAG , 1999, Leukemia.

[33]  C. Leith,et al.  Multidrug resistance in leukemia , 1998, Current opinion in hematology.

[34]  P. Sonneveld,et al.  MDR 1 expression is an independent prognostic factor for response and survival in de novo acute myeloid leukaemia , 1997, British journal of haematology.

[35]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[36]  W. Wilmanns,et al.  Idarubicin monotherapy in multiply pretreated leukemia patients: response in relation to P-glycoprotein expression , 1997, Annals of Hematology.

[37]  M. Slovak,et al.  Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. , 1997, Blood.

[38]  F. DuBru,et al.  Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells. , 1996, Molecular pharmacology.

[39]  I. Bernstein,et al.  Cell surface expression of the multidrug resistance P-glycoprotein (P-170) as detected by monoclonal antibody MRK-16 in pediatric acute myeloid leukemia fails to define a poor prognostic group: a report from the Childrens Cancer Group. , 1995, Leukemia.

[40]  J. Lankelma,et al.  The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity. , 1995, Biochemical pharmacology.

[41]  P. Zinzani,et al.  FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias. , 1994, Leukemia.